EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Residual circulating tumor DNA after adjuvant chemotherapy effectively predicts recurrence of stage II‐III gastric cancer

Shu-Qiang Yuan, Run-Cong Nie iD, You-Sheng Huang, Ying-Bo Chen, Si-Yu Wang, Xiao-Wei Sun, Yuan-Fang Li iD, Ze-Kun Liu, Yan-Xing Chen, Yi-Chen Yao, Yu Xu, Hai-Bo Qiu iD und 7 weitere

Cancer Communications · 2023-12 · 43 (12) · 1312-1325

DOI: 10.1002/cac2.12494 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Communications, online erschienen am 14.10.2023. Verfasst von Shu-Qiang Yuan und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastric Surgery, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China, Collaborative Innovation Center…. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Stomach Neoplasms. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Science and Technology Program of Guangdong, CAMS Innovation Fund for Medical Sciences (CIFMS), International Cooperation and Exchanges National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Circulating tumor DNA (ctDNA) is a promising biomarker for predicting relapse in multiple solid cancers. However, the predictive value of ctDNA for disease recurrence remains indefinite in locoregional gastric cancer (GC). Here, we aimed to evaluate the predictive value of ctDNA in this context.

Methods

From 2016 to 2019, 100 patients with stage II/III resectable GC were recruited in this prospective cohort study (NCT02887612). Primary tumors were collected during surgical resection, and plasma samples were collected perioperatively and within 3 months after adjuvant chemotherapy (ACT). Somatic variants were captured via a targeted sequencing panel of 425 cancer‐related genes. The plasma was defined as ctDNA‐positive only if one or more variants detected in the plasma were presented in at least 2% of the primary tumors.

Results

Compared with ctDNA‐negative patients, patients with positive postoperative ctDNA had moderately higher risk of recurrence [hazard ratio (HR) = 2.74, 95% confidence interval (CI) = 1.37–5.48; P = 0.003], while patients with positive post‐ACT ctDNA showed remarkably higher risk (HR = 14.99, 95% CI = 3.08‐72.96; P < 0.001). Multivariate analyses indicated that both postoperative and post‐ACT ctDNA positivity were independent predictors of recurrence‐free survival (RFS). Moreover, post‐ACT ctDNA achieved better predictive performance (sensitivity, 77.8%; specificity, 90.6%) than both postoperative ctDNA and serial cancer antigen. A comprehensive model incorporating ctDNA for recurrence risk prediction showed a higher C‐index (0.78; 95% CI = 0.71–0.84) than the model without ctDNA (0.71; 95% CI = 0.64–0.79; P = 0.009).

Conclusions

Residual ctDNA after ACT effectively predicts high recurrence risk in stage II/III GC, and the combination of tissue‐based and circulating tumor features could achieve better risk prediction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Circulating Tumor DNAStomach NeoplasmsHumansChemotherapy, AdjuvantNeoplasm Recurrence, LocalProspective StudiesCohort Studies

Stichwörter der Autor:innen

chemotherapyctDNAgastric cancerpostoperativerecurrence

Substanzen

Circulating Tumor DNA

Autor:innen und Institutionen

  • Department of Gastric Surgery, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, P. R. China.
  • Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, Guangdong, P. R. China.
  • Department of Medical Oncology, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, Guangdong, P…
  • Bioinformatics Platform, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P. R. China.

ORCID-Profile: Run-Cong Nie, Yuan-Fang Li, Hai-Bo Qiu, Qi Zhao, Rui-Hua Xu, Feng Wang

Förderung

  • Science and Technology Program of Guangdong
  • CAMS Innovation Fund for Medical Sciences (CIFMS)
  • International Cooperation and Exchanges National Natural Science Foundation of China
  • National Natural Science Foundation of China
  • Sun Yat-sen University Clinical Research 5010 Program
  • Young Physician Scientist Program of Sun Yat-sen University Cancer Center
  • Guangdong Esophageal Cancer Institute Science and Technology Program

Zitieren

APA

Yuan, S. Q., Nie, R. C., Huang, Y. S., Chen, Y. B., Wang, S. Y., Sun, X. W., Li, Y. F., Liu, Z. K., Chen, Y. X., Yao, Y. C., Xu, Y., Qiu, H. B., Liang, Y., Wang, W., Liu, Z. X., Zhao, Q., Xu, R. H., Zhou, Z. W., & Wang, F. (2023). Residual circulating tumor DNA after adjuvant chemotherapy effectively predicts recurrence of stage II‐III gastric cancer. Cancer Communications, 43(12), 1312-1325. https://doi.org/10.1002/cac2.12494

Vancouver

Yuan SQ, Nie RC, Huang YS, Chen YB, Wang SY, Sun XW, et al. Residual circulating tumor DNA after adjuvant chemotherapy effectively predicts recurrence of stage II‐III gastric cancer. Cancer Communications. 2023;43(12):1312-1325. doi:10.1002/cac2.12494

BibTeX
@article{Yuan2023,
  author = {Yuan, Shu-Qiang and Nie, Run-Cong and Huang, You-Sheng and Chen, Ying-Bo and Wang, Si-Yu and Sun, Xiao-Wei and Li, Yuan-Fang and Liu, Ze-Kun and Chen, Yan-Xing and Yao, Yi-Chen and Xu, Yu and Qiu, Hai-Bo and Liang, Yao and Wang, Wei and Liu, Ze-Xian and Zhao, Qi and Xu, Rui-Hua and Zhou, Zhi-Wei and Wang, Feng},
  title = {Residual circulating tumor DNA after adjuvant chemotherapy effectively predicts recurrence of stage II‐III gastric cancer},
  journal = {Cancer Communications},
  year = {2023},
  volume = {43},
  number = {12},
  pages = {1312--1325},
  doi = {10.1002/cac2.12494}
}
Kostenlos starten →